# A Study to Evaluate Once-Daily Oral VT-464 in Patients With Castration-Resistant Prostate Cancer

> **NCT02361086** · PHASE1,PHASE2 · COMPLETED · sponsor: **Innocrin Pharmaceutical** · enrollment: 21 (actual)

## Conditions studied

- Castration-resistant Prostate Cancer
- CRPC

## Interventions

- **DRUG:** VT-464: given orally once daily in 28 day cycles

## Key facts

- **NCT ID:** NCT02361086
- **Lead sponsor:** Innocrin Pharmaceutical
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-06
- **Primary completion:** 2017-12
- **Final completion:** 2018-06
- **Target enrollment:** 21 (ACTUAL)
- **Last updated:** 2019-02-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02361086

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02361086, "A Study to Evaluate Once-Daily Oral VT-464 in Patients With Castration-Resistant Prostate Cancer". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT02361086. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*